NCT06956690View on ClinicalTrials.gov

A Phase 1/2 Clinical Trial to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HMBD-501 in Patients With HER3-Expressing Solid Tumors

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

180

Participants

Timeline

Start Date

October 31, 2025

Primary Completion Date

July 31, 2027

Study Completion Date

July 31, 2027

Conditions
Melanoma (Skin)Non Small Cell Lung CancerBreast Cancer
Interventions
BIOLOGICAL

ENV-501

ENV-501 is a HER3-targeted antibody-drug conjugate (ADC) with a humanized monoclonal antibody (mAb) conjugated with a chemotherapeutic payload via a linker.

Trial Locations (6)

2228

RECRUITING

Research Site, Miranda

2560

RECRUITING

Research Site, Campbelltown

46250

RECRUITING

Research Site, Indianapolis

48334

RECRUITING

Research Site, Farmington Hills

75230

RECRUITING

Research Site, Dallas

92093

RECRUITING

Research Site, La Jolla

Sponsors
All Listed Sponsors
lead

Hummingbird Bioscience

INDUSTRY

NCT06956690 - A Phase 1/2 Clinical Trial to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HMBD-501 in Patients With HER3-Expressing Solid Tumors | Biotech Hunter | Biotech Hunter